# Tempest Therapeutics (stock symbol: TPST) Logo in transparent PNG format

## Tempest Therapeutics Logo large

### Tempest Therapeutics Logo large Download PNG (48.99 KB)

![Tempest Therapeutics Logo large Download PNG (48.99 KB)](/img/orig/TPST_BIG-85f84959.png)

## Tempest Therapeutics Logo icon format

### Tempest Therapeutics Logo icon format Download PNG (152.46 KB)

![Tempest Therapeutics Logo icon format Download PNG (152.46 KB)](/img/orig/TPST-589e0140.png)

## About Tempest Therapeutics

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

1. Website domain: tempesttx.com
2. Employees: 17
3. Marketcap: $22.39 Million USD


## Categories
- [x] ðŸ‡ºðŸ‡¸ United States
- [x] ðŸ’Š Pharmaceuticals
- [x] ðŸ§¬ Biotech
